Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains
The present invention relates to gamma delta (γδ) T cells and/or Natural Killer (NK) cells expressing constructs to provide for the expression of a Chimeric Antigen Receptor (CAR) incorporating the signalling domain of FCY Receptors. Suitably the invention also relates to constructs to provide such CARs and methods for introducing such CARs into cells and expressing such CARs in cells comprising receptors of gamma delta (γδ) T cells and/or Natural Killer (NK) cells.
1. A gamma delta T cell comprising a nucleic acid construct to provide for expression of a CAR comprising:
(i) an antigen-binding domain coupled to a trans-membrane domain, and
(ii) an intracellular activation signalling domain
wherein the intracellular signalling domain consists of one or more Fcγ Receptor intracellular signalling domains, wherein the one or more Fcγ Receptor intracellular signalling domains is from an Fc R common gamma chain, a CD16, a CD32a, a CD32c, or a CD64, and wherein binding of antigen to the antigen binding domain of the CAR causes signalling by the intracellular signalling domain of the CAR.
2. The gamma delta T cell of claim 1 , wherein binding by the gamma delta T cell receptor of the gamma delta T cell to a target ligand to which the gamma delta T cell receptor has binding specificity causes a first intracellular signal and binding of the CAR antigen binding domain to a target ligand to which the CAR has binding specificity causes a second intracellular signal, wherein the first and second intracellular signals alone or in combination cause activation of the gamma delta T cell.
3. The gamma delta T cell of claim 1 , wherein activation of the gamma delta T cell by a target cell causes activation of the gamma delta T cell to promote cell death of the target cell.
4. The gamma delta T cell of claim 1 , comprising a nucleic acid construct encoding a CAR wherein the nucleic acid construct encodes an amino acid sequence selected from at least one of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7, or a combination thereof.
5. The gamma delta T cell of claim 1 wherein:
(a) the one or more Fcγ Receptor intracellular signalling domains comprises at least one CD32a or CD32c or CD 64 signalling domain, such that binding of antigen to the antigen binding domain of the CAR causes signalling by the intracellular signalling domain of the CAR;
(b) the CD32a or CD32c signalling domains have a sequence identity of at least 95% to SEQ ID NO 2 or SEQ ID NO: 3; or
(c) the CAR comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO:7.
6. A pharmaceutical composition comprising a plurality of cells according to claim 1 .
7. A pharmaceutical composition comprising a plurality of cells according to claim 1 .